ONO Pharmaceutical Enters Agreement with Seikagaku for Co-Development and Marketing of Gel-One in Japan, Currently in Phase III Trials
I'm PortAI, I can summarize articles.
ONO Pharmaceutical Co. Ltd. has entered a definitive agreement with Seikagaku Corporation for the co-development and exclusive marketing of Gel-One, a treatment for osteoarthritis in Japan. The product is currently in Phase III clinical trials, focusing on knee and hip osteoarthritis. The collaboration aims to expedite the studies for timely manufacturing and marketing authorization. Ono will pay Seikagaku tiered royalties based on development and marketing progress.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments